Book an appointment and take the first step toward better health
NaV1.7 was once considered one of the most promising targets for non-opioid pain management after the discovery that individuals with loss-of-function mutations are insensitive to pain yet are otherwise healthy
Clinical studies have demonstrated that GLP-1 receptor agonists, including Ozempic , can support meaningful and sustained weight loss over extended periods
national Medicare cohort study, also included 21,402 pairs of patients treated with a GLP-1 RA versus DPP-4 inhibitors and found no differences in suicidal ideation and behaviors between groups [29]
IN has served as a speaker, consultant, and/or advisory board member for Boehringer Ingelheim, Eli Lilly, Bayer Pharmaceuticals, MJH Life Sciences, and Dexcom, Inc
The appetite-suppressing mechanism you want comes with a digestive side effect you do not